In summary, EGFRvIII expression increased the de novo resistance of breast cancer cells against trastuzumab, and the feedback activation of STAT3 caused by trastuzumab also contributed to acquired resistance in EGFRvIII+HER2+ breast cancers. This evidence concerns the gene STAT3 and breast cancer.